14-day Premium Trial Subscription Sign Up For FreeGet Free

CNAT Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -19.43% during the next 3 months and, with a 90% probability hold a price between $0.54 and $0.75 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-09-20 $0.67 $0.80 $0.93
2021-09-21 $0.67 $0.80 $0.92
2021-09-22 $0.66 $0.79 $0.92
2021-09-23 $0.66 $0.79 $0.92
2021-09-24 $0.66 $0.79 $0.91
2021-09-27 $0.65 $0.78 $0.91
2021-09-28 $0.65 $0.78 $0.91
2021-09-29 $0.65 $0.77 $0.90
2021-09-30 $0.64 $0.77 $0.90
2021-10-01 $0.64 $0.77 $0.89
2021-10-04 $0.64 $0.76 $0.89
2021-10-05 $0.63 $0.76 $0.89
2021-10-06 $0.63 $0.76 $0.88
2021-10-07 $0.63 $0.75 $0.88
2021-10-08 $0.62 $0.75 $0.88
2021-10-11 $0.62 $0.75 $0.87
2021-10-12 $0.61 $0.74 $0.87
2021-10-13 $0.61 $0.74 $0.87
2021-10-14 $0.61 $0.74 $0.86
2021-10-15 $0.60 $0.73 $0.86
2021-10-18 $0.60 $0.73 $0.86
2021-10-19 $0.60 $0.72 $0.85
2021-10-20 $0.59 $0.72 $0.85
2021-10-21 $0.59 $0.72 $0.85
2021-10-22 $0.59 $0.71 $0.84
2021-10-25 $0.58 $0.71 $0.84
2021-10-26 $0.58 $0.71 $0.83
2021-10-27 $0.58 $0.70 $0.83
2021-10-28 $0.57 $0.70 $0.83
2021-10-29 $0.57 $0.70 $0.82

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT